Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × fedratinib × Myeloid × Clear all

Phase

Status

Terminated 3 Active not recruiting 2 Withdrawn 1 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4 Tumor-Agnostic 1 Other solid neoplasm 1 Myeloid 1

Conditions

Primary Myelofibrosis 1 Myeloproliferative Disorders 1

Interventions

fludarabine phosphate 122 Cyclophosphamide 115 Imatinib Mesylate 87 Busulfan 83 Peripheral Blood Stem Cell Transplantation 76 Mycophenolic Acid 75 Azacitidine 75 Cytarabine 73 Cyclosporine 68 fludarabine 65 Whole-Body Irradiation 65 Tacrolimus 61 Antilymphocyte Serum 61 Filgrastim 55 nilotinib 52 Methotrexate 51 Melphalan 47 Decitabine 46 Radiotherapy 37 Dasatinib 30 ruxolitinib 29 thymoglobulin 28 Granulocyte Colony-Stimulating Factor 28 Clofarabine 27 Etoposide 26 Thiotepa 25 Stem Cell Transplantation 23 Methylprednisolone 23 Cord Blood Stem Cell Transplantation 23 sargramostim 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03952039 2025-08-28

FREEDOM2

Celgene

Phase 3 Completed

202 enrolled 23 charts

Myeloproliferative Disorders, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡